Published in Ther Drug Monit on August 01, 2008
Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med (2011) 2.43
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther (2015) 1.49
Pharmacogenetics of antidepressant response. J Psychiatry Neurosci (2011) 1.28
Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol (2012) 1.00
From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment. Can J Psychiatry (2014) 0.93
The promise and reality of pharmacogenetics in psychiatry. Psychiatr Clin North Am (2010) 0.92
Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats. Br J Pharmacol (2012) 0.87
Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance. Br J Clin Pharmacol (2014) 0.83
Pharmacogenetics of antidepressants. Front Pharmacol (2011) 0.82
ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression. Pharmacogenomics J (2014) 0.82
P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents. Neuropsychopharmacology (2013) 0.80
Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors. J Neural Transm (Vienna) (2014) 0.80
Towards the clinical implementation of pharmacogenetics in bipolar disorder. BMC Med (2014) 0.80
Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model. Psychopharmacology (Berl) (2010) 0.78
ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram. Int J Legal Med (2013) 0.77
Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs. Dialogues Clin Neurosci (2016) 0.75
The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key? Int J Mol Sci (2016) 0.75
Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems. Eur J Clin Pharmacol (2015) 0.75
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 3.32
Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res (2002) 3.31
Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry (2005) 1.89
Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval. Arch Intern Med (2010) 1.87
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics (2009) 1.79
ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther (2006) 1.49
Lithium monitoring by reverse iontophoresis in vivo. Clin Chem (2004) 1.47
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther (2005) 1.45
Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. J Clin Psychopharmacol (2012) 1.44
Further delineation of genotype-phenotype correlation in homozygous 2p21 deletion syndromes: first description of patients without cystinuria. Am J Med Genet A (2013) 1.43
Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. J Clin Psychiatry (2015) 1.40
Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology (2005) 1.23
Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med (2012) 1.19
Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. J Clin Psychiatry (2004) 1.14
Efficacy of psychoeducational approaches on bipolar disorders: a review of the literature. J Affect Disord (2006) 1.13
Depression relapse prophylaxis with Mindfulness-Based Cognitive Therapy: replication and extension in the Swiss health care system. J Affect Disord (2009) 1.11
The metalloprotease meprinbeta processes E-cadherin and weakens intercellular adhesion. PLoS One (2008) 1.07
Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring. CNS Drugs (2009) 1.07
Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol (2005) 1.06
Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety. CNS Drugs (2009) 1.05
The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics (2009) 1.05
Dosage changes of MED13L further delineate its role in congenital heart defects and intellectual disability. Eur J Hum Genet (2013) 1.04
CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit (2008) 1.04
ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol (2009) 1.03
Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients. Prog Neuropsychopharmacol Biol Psychiatry (2005) 1.01
Prevalence of substance use in a Swiss psychiatric hospital: interview reports and urine screening. Addict Behav (2005) 1.01
Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. Ther Drug Monit (2008) 1.01
Screening for bipolar disorders using a French version of the Mood Disorder Questionnaire (MDQ). J Affect Disord (2005) 1.00
Motivations to play specifically predict excessive involvement in massively multiplayer online role-playing games: evidence from an online survey. Eur Addict Res (2011) 1.00
Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res (2008) 0.99
Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics (2008) 0.99
Early telephone intervention for psychiatric outpatients starting antidepressant treatment. Nord J Psychiatry (2010) 0.99
Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology (Berl) (2005) 0.98
Retracted Childhood maltreatment and methylation of the glucocorticoid receptor gene NR3C1 in bipolar disorder. Br J Psychiatry (2013) 0.97
The DEX/CRH neuroendocrine test and the prediction of depressive relapse in remitted depressed outpatients. J Psychiatr Res (2006) 0.97
Lithium: updated human knowledge using an evidence-based approach: Part I: Clinical efficacy in bipolar disorder. CNS Drugs (2009) 0.96
Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol (2002) 0.96
Wearable monitoring for mood recognition in bipolar disorder based on history-dependent long-term heart rate variability analysis. IEEE J Biomed Health Inform (2013) 0.94
Mindful Attention Awareness Scale (MAAS): Psychometric properties of the French translation and exploration of its relations with emotion regulation strategies. Psychol Assess (2009) 0.94
Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry (2008) 0.93
Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study. Pharmacogenet Genomics (2013) 0.92
Complex interaction of circadian and non-circadian effects of light on mood: shedding new light on an old story. Sleep Med Rev (2012) 0.92
Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacol (2002) 0.92
Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int J Neuropsychopharmacol (2005) 0.92
In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites. Pharmacology (2007) 0.92
The neural substrates of social emotion perception and regulation are modulated by adult attachment style. Soc Neurosci (2012) 0.91
Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. Clin Pharmacol Ther (2004) 0.91
Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women. Antivir Ther (2012) 0.90
Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clin Pharmacol Ther (2006) 0.90
Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Eur J Clin Pharmacol (2003) 0.90
Quality of Web-based information on depression. Depress Anxiety (2010) 0.90
Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clin Pharmacokinet (2013) 0.89
Quality of web-based information on pathological gambling. J Gambl Stud (2008) 0.89
Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. J Clin Psychopharmacol (2007) 0.89
Risperidone-induced symptomatic hyperprolactinaemia in adolescents. J Clin Psychopharmacol (2006) 0.89
Affective response to a loved one's pain: insula activity as a function of individual differences. PLoS One (2010) 0.88
Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend (2003) 0.88
Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. PLoS One (2013) 0.88
Smoking in psychiatric inpatients: association with working status, diagnosis, comorbid substance abuse and history of suicide attempts. Addict Behav (2009) 0.87
Mental disorders in offspring of parents with bipolar and major depressive disorders. Bipolar Disord (2012) 0.87
No human tryptophan hydroxylase-2 gene R441H mutation in a large cohort of psychiatric patients and control subjects. Biol Psychiatry (2006) 0.87
Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics (2011) 0.86
A novel 2D-based approach to the discovery of candidate substrates for the metalloendopeptidase meprin. FEBS J (2008) 0.86
Is there a place for tricyclic antidepressants and subsequent augmentation strategies in obtaining remission for patients with treatment resistant depression? Pharmacol Res (2008) 0.86
Plasma corticosterone, dexamethasone (DEX) suppression and DEX/CRH tests in a rat model of genetic vulnerability to depression. Psychoneuroendocrinology (2007) 0.85
Influence of CRTC1 polymorphisms on body mass index and fat mass in psychiatric patients and the general adult population. JAMA Psychiatry (2013) 0.85
Blood pressure in relation to coffee and caffeine consumption. Curr Hypertens Rep (2014) 0.85
Speech analysis for mood state characterization in bipolar patients. Conf Proc IEEE Eng Med Biol Soc (2012) 0.85
Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit (2005) 0.85
Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. J Psychopharmacol (2010) 0.85
Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response. J Clin Psychopharmacol (2004) 0.84
Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. J Psychiatr Res (2012) 0.84